XOMA Royalty Corp
No enriched coverage for $XOMA in the last 7 days.
XOMA Royalty said Ligand Pharmaceuticals (Nasdaq: LGND) completed its acquisition of XOMA Royalty. Under the April 27 deal, XOMA shareholders received $39.00 cash per share and one non-transferable CVR per share tied to 75% of net proceeds from certain pending litigation. XOMA shares no longer trade on Nasdaq.
XOMA Royalty Corp (XOMA) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. 8-K XOMA Royalty Corp false 0000791908 0000791908 2026-07-13 2026-07-13 0000791908 us-gaap:CommonStockMember 2026-07-13 2026-07-13 0000791908 xoma:M8.625SeriesACumulativePerpetualPreferredStockParValue0.05PerShareMember 2026-07-13 2026-07-13 0000791908 xoma:DepositarySharesEachRe
XOMA Royalty Corp. said its board authorized quarterly dividends on its preferred stock: $0.53906 per share for the 8.625% Series A (XOMAP) and $0.52344 per depositary share for the 8.375% Series B (XOMAO). Dividends are payable about July 15, 2026 to holders of record July 2. The company will redeem all outstanding preferred stock on July 14, 2026 at $25.00 per share/depositary share, with dividends stopping after redemption. The redemption is tied to XOMA’s pending merger with Flex Merger Sub,
Recent XOMA coverage spans financial news and mergers & acquisitions.
In the last 30 days, XOMA insiders filed 8 SEC Form 4 transactions — no purchases and 8 sales. The most active reporter was Sitko Bradley, Chief Investment Officer, with 4 filings.
Deal close is a definitive liquidity and corporate-action event for XOMA, with shares no longer trading on Nasdaq.
Deal closing and consideration mechanics are now effective, shifting XOMA equity risk from operating to CVR/transaction execution.
Preferred-stock redemption and CVR record-date mechanics are near-term capital-structure events that can affect XOMA’s equity/rights trading into mid-July.
The conversion of preferred shares into common stock by BVF group suggests increased insider confidence and potential for stock price appreciation. This transaction may signal a bullish outlook, but also warrants caution due to insider ownership concentration.
The director's exercise of options and increased holdings suggest confidence in XOMA's future prospects, which could be a bullish signal for the stock.
alphai scores every news story that mentions XOMA with an AI model for sentiment and relevance, and aggregates insider trades from XOMA Royalty Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
XOMA Royalty said Ligand Pharmaceuticals (Nasdaq: LGND) completed its acquisition of XOMA Royalty. Under the April 27 deal, XOMA shareholders received $39.00 cash per share and one non-transferable CVR per share tied to 75% of net proceeds from certain pending litigation. XOMA shares no longer trade on Nasdaq.
2 min readXOMA Royalty Corp (XOMA) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. 8-K XOMA Royalty Corp false 0000791908 0000791908 2026-07-13 2026-07-13 0000791908 us-gaap:CommonStockMember 2026-07-13 2026-07-13 0000791908 xoma:M8.625SeriesACumulativePerpetualPreferredStockParValue0.05PerShareMember 2026-07-13 2026-07-13 0000791908 xoma:DepositarySharesEachRe
2 min readXOMA Royalty Corp. said its board authorized quarterly dividends on its preferred stock: $0.53906 per share for the 8.625% Series A (XOMAP) and $0.52344 per depositary share for the 8.375% Series B (XOMAO). Dividends are payable about July 15, 2026 to holders of record July 2. The company will redeem all outstanding preferred stock on July 14, 2026 at $25.00 per share/depositary share, with dividends stopping after redemption. The redemption is tied to XOMA’s pending merger with Flex Merger Sub,
4 min readBVF group entities converted 5,003 shares of XOMA Royalty Corp's Series X Convertible Preferred Stock into 5,003,000 shares of common stock at $4.03 per share on May 14, 2026. This transaction changed the form of ownership from preferred to common stock for the reporting group, which is a Section 13(d) group owning over 10% of XOMA common stock. The conversions are exempt from short-swing profit rules under Rule 16b-6(b).
2 min readXOMA Royalty Corp director Joseph M. Limber exercised stock options to acquire 3,026 shares of common stock at $11.20 per share. These options had been fully vested since July 21, 2017, and are now fully exercised. Following this transaction, Mr. Limber directly holds 9,234 shares of common stock, 20,000 depositary shares of 8.375% Series B cumulative stock, and 10,000 shares of 8.625% Series A cumulative perpetual preferred stock.
2 min readPomerantz LLP is investigating potential claims against XOMA Royalty Corporation after its development partner, Rezolute, Inc., announced that a Phase 3 study for ersodetug in congenital hyperinsulinism failed to meet its primary and secondary endpoints. This news led to a significant 22.76% drop in XOMA's stock price, prompting the firm to investigate possible securities fraud or unlawful business practices. Investors affected by the stock decline are encouraged to contact Pomerantz LLP.
4 min readXOMA Royalty Corporation (NASDAQ: XOMA) has agreed to acquire Generation Bio Co. (NASDAQ: GBIO) for $4.2913 per share in cash, plus contingent value rights (CVRs). The CVRs entitle Generation Bio stockholders to potential future payments from net cash, lease savings, proceeds from Generation Bio's Moderna collaboration, and any sale or out-license of Generation Bio's cell-targeted lipid nanoparticle (ctLNP) delivery platform. The acquisition will include a tender offer and is expected to close in February 2026.
3 min readXOMA Royalty Corporation has transformed from a biopharmaceutical developer into a specialized biotechnology royalty aggregator, acquiring rights to future milestone and royalty payments from therapeutic candidates. This model allows XOMA to generate revenue without the high costs and risks of drug development, providing crucial non-dilutive funding to biotech companies. Despite a recent clinical trial setback, XOMA maintains a diversified portfolio, strong financial health, and positive analyst outlook, focusing on strategic acquisitions and earlier-stage assets for long-term growth.
4 min readWALTHAM, Mass. and DUBLIN, Ireland, Nov. 26, 2025 ( GLOBE NEWSWIRE ) -- Mural Oncology plc ( NASDAQ:MURA ) ( "Mural" ) announces that, in accordance with the terms of the transaction agreement between XOMA Royalty Corporation ( NASDAQ:XOMA ) ( "XOMA Royalty" ) , XRA 5 Corp. ( "Sub" ) and Mural ...
2 min readEMERYVILLE, Calif., Nov. 21, 2025 ( GLOBE NEWSWIRE ) -- XOMA Royalty Corporation ( "XOMA Royalty" ) ( NASDAQ:XOMA ) today announced it has successfully completed its previously announced acquisition of all the outstanding common shares of LAVA Therapeutics N.V. ( "LAVA" ) ( NASDAQ:LVTX ) with a ...
4 min read
